Education:

University of Minnesota, 1984, MD
Saint Olaf College, 1979, BA

Research Focus:

Hematopoietic cell transplant (HCT) is the only curative therapy for many life-threatening hematologic diseases, and theoretically could cure other chronic hematologic and immunologic disorders. The research projects under Dr. Woolfrey’s direction are aimed toward improving the effectiveness of hematopoietic cell transplants, particularly for patients with nonmalignant disorders. These studies explore the use of reduced intensity conditioning regimens to reduce the short and long term toxicities associated with HCT, the use of HCT to restore normal immunity in patients with HIV or refractory autoimmune diseases, and the use of alternative donors, including unrelated and mismatched related donors. Several studies will be opened this year, focused on transplant of gene modified cells to treat HIV or genetic diseases.

A Prospective Trial to Evaluate the Role of In Vivo T Cell Depletion by Campath® (Alemtuzumab) in Reduction of Transplant Related Mortality in Transplantation from HLA-Class I or Class II Mismatched, Unrelated Donors

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications

Phase I Feasibility Study of Clofarabine and Low Dose Total Body Irradiation (TBI) as a Non-myeloablative Preparative Regimen for Stem Cell Transplantation (SCT) for Hematological Malignancies: a Multi-Center Study

A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBU’s) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients

Protocol for a Research Sample Repository for Allogeneic Hemtopoietic Stem Cell Transplantation